What's Happening?
American Airlines has announced changes to its healthcare plan for flight attendants, effective January 1, 2026. The new policy will restrict coverage of GLP-1 medications, such as Ozempic, to employees
diagnosed with type 2 diabetes. This decision has sparked frustration among the Association of Professional Flight Attendants (APFA), as many members rely on these medications for weight management. The union has proposed alternatives like copay caps and prior authorization requirements to mitigate the impact, but American Airlines has opted for outright exclusion. The union is urging affected members to voice their concerns to company representatives.
Why It's Important?
The exclusion of Ozempic from healthcare coverage for non-diabetic flight attendants could have significant implications for employee health and morale. Ozempic is known for its effectiveness in weight management, and its retail cost of approximately $1,000 per month makes it unaffordable for many without insurance coverage. This change may lead to increased healthcare costs for employees and could affect their overall well-being. Additionally, the decision reflects American Airlines' efforts to manage high labor costs amid financial challenges, potentially impacting its competitiveness compared to other airlines like Delta and United.
What's Next?
The union plans to continue advocating for the inclusion of Ozempic in the healthcare plan for weight management purposes. As the policy change approaches, flight attendants may increase pressure on American Airlines through direct communication and public advocacy. The broader industry may also watch closely, as similar cost-cutting measures could be considered by other airlines facing financial pressures.